论文部分内容阅读
氨基糖甙类在成人的毒性了解得颇多,然而对新生儿肾的影响报道甚少。近来有报道新生儿用庆大或妥布霉素治疗可能发生来源于肾小管细胞的尿酶活性增高,特别是丙氨酸氨基肽酶(AAP)和N-乙酰-β-氨基葡萄糖苷酶(NAG)的增高。虽然尿酶的临床重要性尚未确定,但尿酶增高是临床肾损害的早期征象。本文研究新生儿用妥布霉素和头孢噻甲羧肟治疗期间的尿酶(AAP和NAG)活性改变,以了解其对肾脏的毒性。作者随机选择了66例怀疑新生儿败血症的病例,用妥布霉素和头孢噻甲羧肟与氨苄青霉素配
Aminoglycosides in adults to understand a lot of toxicity, however, little effect on neonatal kidney. It has recently been reported that neonatal treatment with Qingbai or tobramycin may occur from renal tubular cells increased urinary enzyme activity, especially alanine aminopeptidase (AAP) and N-acetyl-β-glucosaminidase NAG) increased. Although the clinical importance of urease has not been established, increased urinary enzymes are an early sign of clinical kidney damage. This article investigates changes in urease (AAP and NAG) activity in newborns treated with tobramycin and ceftazidime to understand their toxicity to the kidneys. The authors randomly selected 66 cases of suspected neonatal sepsis cases, with tobramycin and ceftiostat oxime with ampicillin with